BioAtla, Inc. Share Price
BCABBioAtla, Inc. Stock Performance
Open $0.69 | Prev. Close $0.67 | Circuit Range N/A |
Day Range $0.69 - $0.75 | Year Range $0.24 - $1.42 | Volume 17,470 |
Average Traded $0.74 |
BioAtla, Inc. Share Price Chart
About BioAtla, Inc.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
BioAtla, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
24-Dec-25 | $0.69 | $0.72 | +0.00% |
24-Dec-25 | $0.69 | $0.72 | +7.89% |
23-Dec-25 | $0.78 | $0.67 | -17.04% |
22-Dec-25 | $0.77 | $0.81 | +7.57% |
19-Dec-25 | $0.79 | $0.75 | -4.92% |
18-Dec-25 | $0.80 | $0.79 | +1.54% |
17-Dec-25 | $0.75 | $0.78 | +0.91% |
FAQs on BioAtla, Inc. Share Price
Can I buy BioAtla, Inc. shares in India?
What is the share price of BioAtla, Inc.?
What is the 5 year returns of BioAtla, Inc.?
What are the high & low stock price of BioAtla, Inc. today?
What is the 52-week high and low of BioAtla, Inc. stock?